Related Experiment Video
Updated: May 7, 2026
In Vivo Tracking of Human Adipose-derived Mesenchymal Stem Cells in a Rat Knee Osteoarthritis Model with Fluorescent Lipophilic Membrane Dye
Published on: October 8, 2017
Global clinical trial landscape of stem cell-based therapies for osteoarthritis: trends and translational
Xin Li1, Yue Zhao2, Dongsheng Guo1
1Department of Orthopedics, The Affiliated Lianyungang Hospital of Xuzhou Medical University (The First People's Hospital of Lianyungang), Lianyungang, Jiangsu, China.
Objective:
Osteoarthritis (OA) is a leading cause of pain and disability worldwide, yet disease-modifying treatments remain limited. This study aimed to map the global registry landscape of interventional clinical trials of stem cell-based therapies for OA and summarize temporal, geographic, and design trends.
Methods:
We conducted a systematic, registry-based landscape analysis of interventional clinical trials assessing stem cell therapies for osteoarthritis. Trial records were obtained from the Informa Pharmaprojects platform. Two researchers extracted and summarized trial characteristics, including year, phase, geographic distribution, target joint, cell source or type, autologous versus allogeneic strategy, administration route, outcome measures, and trial status. We then performed a descriptive trend analysis.
Results:
We identified a total of 224 eligible trials. The number of trials has steadily increased over time, with broad international participation. Most studies focused on knee osteoarthritis and used intra-articular administration. Mesenchymal stem cell-based products dominated, encompassing both autologous and allogeneic approaches, with growing attention to scalable allogeneic strategies. Primary endpoints were typically patient-reported pain and functional measures, while imaging and biomarker outcomes were often secondary. Published evidence syntheses suggest potential benefits in terms of pain and function, but conclusions are frequently limited by heterogeneity, risk of bias, and relatively short follow-up durations.
Conclusion:
The number of stem cell-based clinical trials for osteoarthritis is increasing globally, but heterogeneity in study designs and incomplete public reporting limit reliable conclusions about efficacy. Future research should prioritize standardizing products and protocols, employing more rigorous comparators and feasible blinding, extending follow-up periods, and ensuring transparent reporting to facilitate clinical translation.
Insights
Global clinical trials for osteoarthritis stem cell therapies are rising, but inconsistent designs and reporting hinder efficacy conclusions. Standardization and longer follow-ups are crucial for translating these regenerative medicine approaches.
Area of Science:
- Regenerative Medicine
- Clinical Trial Analysis
- Osteoarthritis Therapeutics
Background:
- Osteoarthritis (OA) is a major cause of global pain and disability.
- Current disease-modifying treatments for OA are limited.
- Stem cell-based therapies offer a potential avenue for OA treatment.
Purpose of the Study:
- To map the global landscape of interventional clinical trials for stem cell therapies in OA.
- To analyze temporal, geographic, and design trends in these trials.
- To identify challenges and future directions for stem cell therapy research in OA.
Main Methods:
- A systematic, registry-based landscape analysis was performed.
- Data were sourced from the Informa Pharmaprojects platform.
- Trial characteristics (phase, location, cell type, administration, outcomes) were extracted and analyzed for trends.
Main Results:
- 224 eligible trials were identified, showing a steady global increase over time.
- Mesenchymal stem cells, particularly allogeneic, were dominant, often administered intra-articularly for knee OA.
- While some studies suggest benefits, heterogeneity and short follow-ups limit definitive conclusions on efficacy.
Conclusions:
- The number of stem cell trials for OA is growing internationally.
- Heterogeneity in study design and incomplete reporting impede reliable efficacy conclusions.
- Future research requires standardized protocols, rigorous comparators, extended follow-up, and transparent reporting for clinical translation.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...